Xgene Pharmaceutical Group

The landmark US approval of Vertex’s non-opioid pain drug Journavx last week could open up the market for other companies with new therapies without addictive potential. One of these, Algiax Pharmac

Vertex Pharmaceuticals’ Journavx (suzetrigine) has gained US Food and Drug Administration approval for acute pain, but the question now is how well it might fare commercially, with analysts forecastin

It has been a challenge for decades in the central nervous system (CNS) to discover a new target for pain relief that is both safe and can also compete with, or even replace, opioid options. In Decemb

The recent partial success of Vertex Pharmaceuticals Incorporated ’s non-opioid product VX-548 in a pair of acute pain studies positions the product as potentially the first new non-opioid analgesic